Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJingbo Yu

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals Ruxolitinib significantly reduces phlebotomy use in polycythemia vera patients over 4 years.

Key Points

  • This research aimed to evaluate the duration of Ruxolitinib treatment and its impact on phlebotomy needs in patients with polycythemia vera.
  • Retrospective analysis of Medicare Fee-For-Service claims data
  • Inclusion of patients with polycythemia vera based on ICD-10 codes
  • Evaluation of treatment duration and phlebotomy use pre- and post-Ruxolitinib initiation
  • Median Ruxolitinib treatment duration was 42 months
  • 60% of patients who required phlebotomy at baseline became phlebotomy-free within 6 months after starting Ruxolitinib
  • 3.6 years of continuous Ruxolitinib treatment was observed, indicating sustained clinical benefit

Cite This Study

Jingbo Yu (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7f7https://doi.org/10.1182/blood-2025-2826
View Full Paper
Ask AI
Bookmark
Share